The effect of CYP2C19 gene polymorphism and clopidogrel dose on clinical outcomes in Asian populations with CAD receiving antiplatelet therapy

被引：0
|
作者：
Liu, W. [1 ]
Xi, Z. W. [1 ]
Zhou, Y. J. [1 ]
机构：
[1] Beijing Anzhen Hosp, Caridiol, Beijing, Peoples R China
来源：
EUROPEAN HEART JOURNAL | 2017年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2867
引用
收藏
页码：613 / 613
页数：1
相关论文
共 50 条
  • [41] The impact of CYP2C19 and CYP4F2 variants and clinical factors on treatment outcomes during antiplatelet therapy
    Tatarunas, Vacis
    Kupstyte-Kristapone, Nora
    Norvilaite, Rita
    Tamakauskas, Vytenis
    Skipskis, Vilius
    Audrone, Veikutiene
    Jurgaityte, Julija
    Stuoka, Mantvydas
    Lesauskaite, Vaiva
    PHARMACOGENOMICS, 2019, 20 (07) : 483 - 492
  • [42] Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy
    Abdullah M. Al-Rubaish
    Fahad A. Al-Muhanna
    Abdullah M. Alshehri
    Mohammed A. Al-Mansori
    Rudaynah A. Alali
    Rania M. Khalil
    Khalid A. Al Faraidy
    Cyril Cyrus
    Mohammed M. Sulieman
    Chittibabu Vatte
    Daniel M. F. Claassens
    Jurriën M. ten Berg
    Folkert W. Asselbergs
    Amein K. Al-Ali
    BMC Cardiovascular Disorders, 20
  • [43] Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions
    Klein, Melissa D.
    Lee, Craig R.
    Stouffer, George A.
    PHARMACOGENOMICS, 2018, 19 (13) : 1039 - 1046
  • [44] CYP2C19 Genotype-Guided Antiplatelet Therapy and Clinical Outcomes in Patients Undergoing a Neurointerventional Procedure
    Tunehag, Kayla R.
    Pearce, Ashton F.
    Fox, Layna P.
    Stouffer, George A.
    Solander, Sten
    Lee, Craig R.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2025, 18 (01):
  • [45] THE ANTIPLATELET EFFECT OF CLOPIDOGREL IS WEAKER FOR JAPANESE PATIENTS PROBABLY DUE TO FREQUENT CYP2C19 POLYMORPHISMS
    Kita, T.
    Jinnai, T.
    Makiyama, T.
    Horiuchi, H.
    Kimura, T.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [46] Protective effect of the CYP2C19*17 polymorphism with increased activation of clopidogrel on cardiovascular events
    Tiroch, Klaus A.
    Sibbing, Dirk
    Koch, Werner
    Roosen-Runge, Tobias
    Mehilli, Julinda
    Schoemig, Albert
    Kastrati, Adnan
    AMERICAN HEART JOURNAL, 2010, 160 (03) : 506 - 512
  • [47] Influence of CYP2C19 and ABCB1 polymorphisms in antiplatelet treatment with clopidogrel
    Davila-Fajardo, C. L.
    Garcia, C.
    Gomez, C.
    Marin, C.
    Cabeza, J.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (05) : 874 - 874
  • [48] CYP2C19 Polymorphisms and Antiplatelet Effects of Clopidogrel in Acute Ischemic Stroke in China
    Jia, Dong-mei
    Chen, Zhi-bin
    Zhang, Mei-juan
    Yang, Wen-jie
    Jin, Jia-li
    Xia, Yong-quan
    Zhang, Chun-lei
    Shao, Yuan
    Chen, Cong
    Xu, Yun
    STROKE, 2013, 44 (06) : 1717 - 1719
  • [49] IMPACT OF CYP2C19 GENOTYPING FOR IDENTIFICATION OF PATIENTS WITH ATTENUATED ANTIPLATELET RESPONSE TO CLOPIDOGREL
    Trenk, D.
    Hochholzer, W.
    Fromm, M. F.
    Zolk, O.
    Neumann, F. -J.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 : 2 - 2
  • [50] Aiming for precision: CYP2C19 gene polymorphism and clopidogrel resistance in patients with peripheral artery disease
    Rashedi, Sina
    Sadeghipour, Parham
    Lou, Junyang
    THROMBOSIS RESEARCH, 2024, 236 : 240 - 241
12345